Thelansis

Pompe Disease Emerging Therapy and TPP Insights Thelansis’s “Pompe Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Pompe Disease Overview Pompe disease is a rare, progressive autosomal recessive lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA) — encoded by the GAA gene — resulting in pathological intralysosomal glycogen accumulation predominantly within skeletal, cardiac, and smooth muscle, causing irreversible cellular damage and organ dysfunction. Disease severity correlates inversely with residual GAA enzyme activity, producing a clinical spectrum ranging from classic infantile-onset Pompe disease — presenting within months of birth with hypertrophic cardiomyopathy, profound hypot...

Pompe Disease Emerging Therapy and TPP Insights Thelansis’s “Pompe Disease Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Target Product Profiles Attributes and levels Physic...

Pompe Disease Market Outlook Thelansis’s “Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Pompe Disease Overview Pompe disease is a rare, progressive autosomal recessive lysosomal storage disorder caused by deficiency of acid alpha-glucosidase (GAA) — encoded by the GAA gene — resulting in pathological intralysosomal glycogen accumulation predominantly within skeletal, cardiac, and smooth muscle, causing irreversible cellular damage and organ dysfunction. Disease severity correlates inversely with residual GAA enzyme activity, producing a clinical ...

Pompe Disease Market Outlook Thelansis’s “ ⁠ Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 ”  covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential ⁠ Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China) . Key business questions answered: How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have t...

Pompe Disease Market Outlook Thelansis’s “Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What insights do inter...

Pompe Disease Market Outlook Thelansis’s “Pompe Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pompe Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Pompe Disease Overview Pompe disease, also known as glycogen storage disease type II (GSD2), is a metabolic disorder caused by mutations in the GAA gene on chromosome 17q25.3. These mutations lead to the synthesis of an insufficient or absent form of the lysosomal enzyme alpha-glucosidase. This results in the accumulation of glycogen within lysosomes in muscular tissue, leading to impairments in striated muscular cells. GSD2 can present as either an early-onset (in...

 Pompe disease, also known as glycogen storage disease type II (GSD2), is a metabolic disorder caused by mutations in the GAA gene on chromosome 17q25.3. These mutations lead to the synthesis of an insufficient or absent form of the lysosomal enzyme alpha-glucosidase. This results in the accumulation of glycogen within lysosomes in muscular tissue, leading to impairments in striated muscular cells. GSD2 can present as either an early-onset (infantile, classic) or late-onset (non-classic) form. Early-onset GSD2 is severe and often fatal without prompt treatment, with respiratory insufficiency and left ventricular outflow obstruction as common causes of mortality. Late-onset GSD2 also results in respiratory insufficiency but at a later age. Enzyme replacement therapy (ERT) is currently the most effective treatment for GSD2. By introducing an analogous enzyme, lysosomal glycogen accumulation in cardiac and skeletal muscle is reduced. The timing of diagnosis is a critical factor in det...

  Pompe disease is an autosomal recessive disorder caused by a deficiency of the enzyme alpha-glucosidase (GAA), resulting in the lysosomal accumulation of glycogen in multiple organs with prominent involvement in the heart and skeletal muscle. A deficiency causes it in the lysosomal enzyme acid alpha-glucosidase. The clinical presentation is heterogeneous, mainly due to the amount of residual GAA enzyme activity associated with different mutations in the GAA gene. Thus, Pompe disease varies concerning the age at onset, disease progression, and extent of organ involvement. It is an uncommon cause of the floppy baby syndrome and is thus often overlooked in early differential diagnoses of infants. The estimated incidence of infantile forms of Pompe disease ranges between 1.5 to 2.7 cases per every 120,000 births, and the late-onset form ranges between 1 to 2 cases per 60,000 births. Thelansis’s “Pompe Disease Market Outlook, Epidemiology, Competitive Landscape , ...